natgillin/translations-raw huggingface dataset:
Oprymea can be taken with or without food. 
Oprymea se može uzimati sa ili bez hrane.
Patients with kidney disease If you have severe kidney disease, Oprymea may not be a suitable treatment for you. 
Ako imate tešku bolest bubrega, Oprymea možda neće biti prikladna za Vaše liječenje.
Swallow whole, do not chew, divide or crush. 
Progutati cijelu tabletu, ne žvakati, dijeliti ili drobiti.
Further dose adjustments should be done based on the clinical response and the occurrence of adverse reactions. 
Dodatno prilagođavanje doze potrebno je provesti prema kliničkom odgovoru i pojavi nuspojava.
Pramipexole is bound to plasma proteins to a very low (< 20%) extent, and little biotransformation is seen in man. 
Pramipeksol se u vrlo maloj mjeri veže na proteine plazme (<20%), te se malo biotransformira u ljudi.
If use of Oprymea is unavoidable, breast-feeding should be stopped. 
Ako je primjena lijeka Oprymea neizbježna, potrebno je prekinuti dojenje.
Not known 
Nepoznato:
Oprymea is used to treat the symptoms of primary Parkinson's disease in adults. 
Oprymea se primjenjuje u liječenju simptoma primarne Parkinsonove bolesti u odraslih.
It is recommended that the dose of levodopa is reduced during both the dose escalation and the maintenance treatment with Oprymea, depending on reactions in individual patients (see section 4.5). 
Preporučuje se smanjiti dozu levodope za vrijeme postupnog povećanja doze, kao i za vrijeme terapije održavanja lijekom Oprymea, ovisno o reakcijama pojedinog bolesnika (vidjeti dio 4.5).
In a 26 week placebo controlled trial, rebound of RLS symptoms (worsening of symptom severity as compared to baseline) was observed in 10% of patients (14 out of 135) after abrupt discontinuation of treatment. 
U 26-tjednom placebom kontroliranom ispitivanju primijećen je “rebound” fenomen simptoma sindroma nemirnih nogu (pogoršanje težine simptoma u usporedbi s početnim vrijednostima) u 10% bolesnika (14 od 135) nakon naglog prekida liječenja.
CGI-I responder rates (improved, very much improved) were 51.2% and 72.0% for placebo and pramipexole, respectively (difference 20% CI 95%: 8.1%; 31.8%, p<0.0005). 
Stope bolesnika s odgovorom prema CGI-I (poboljšanje, poboljšanje u velikoj mjeri) bile su 51,2% za placebo i 72,0% za pramipeksol (razlika 20% CI 95%: 8,1%; 31,8%, p<0,0005).
Pramipexole is commonly associated with somnolence and has been associated uncommonly with excessive daytime somnolence and sudden sleep onset episodes (see also section 4.4). 
Pramipeksol je često povezan sa somnolencijom te se manje često povezuje s pojavom prekomjerne dnevne somnolencije i epizodama iznenadnog usnivanja (vidjeti također dio 4.4).
Oprymea has been associated with sleepiness and episodes of suddenly falling asleep, particularly in patients with Parkinson's disease. 
Oprymea je povezana s pospanošću i epizodama iznenadnog usnivanja, osobito u bolesnika s Parkinsonovom bolešću.
Each pack of 21 prolonged-release tablets for a 3-week treatment schedule contains: 7 tablets of Oprymea 0.26 mg 
Svako pakiranje s 21 tabletom s produljenim oslobađanjem za plan liječenja za 3 tjedna sadrži: 7 Oprymea 0,26 mg tableta
Very common: - Nausea (sickness). 
Vrlo često: mučnina
Oprymea is used to: - treat the symptoms of primary Parkinson's disease in adults. 
Oprymea se primjenjuje u: liječenju simptoma primarne Parkinsonove bolesti u odraslih.
Pramipexole prolonged-release tablets were non-inferior to pramipexole immediate release tablets as assessed on the UPDRS Parts II+III score at week 33. 
Pramipeksol tablete s produljenim oslobađanjem nisu bile inferiorne pramipeksol tabletama s trenutnim oslobađanjem, ocjenjivano prema rezultatu UPDRS ljestvice, dijelovima II+III nakon 33 tjedna.
In patients pramipexole alleviates signs and symptoms of idiopathic Parkinson' s disease. 
U bolesnika pramipeksol otklanja znakove i simptome idiopatske Parkinsonove bolesti.
In patients with a creatinine clearance between 30 and 50 ml/min, treatment should be started with 0.26 mg Oprymea prolonged-release tablets every other day. 
U bolesnika s klirensom kreatinina između 30 i 50 ml/min, liječenje treba započeti s Oprymea 0,26 mg tabletom s produljenim oslobađanjem svaki drugi dan.
Some patients have reported the occurrence of remnants in faeces which may resemble intact Oprymea prolonged-release tablets. 
Neki su bolesnici prijavili pojavu ostataka u stolici koji bi mogli nalikovati čitavim Oprymea tabletama s produljenim oslobađanjem.
Boxes of 10, 30, 90 and 100 tablets in blisters of 10 tablets are available. 
Dostupne su kutije od 10, 30, 90 i 100 tableta u blisterima od 10 tableta.
Oprymea prolonged-release tablets are a once-a-day oral formulation of pramipexole. 
Oprymea tablete s produljenim oslobađanjem su jednokratna dnevna oralna formulacija pramipeksola.
Blister (OPA/Alu/desiccant/PE-Alu foil): 10, 30, 90 or 100 prolonged-release tablets, in a box. 
Blister (OPA/Al/desikant/PE-Al folija): 10, 30, 90 ili 100 tableta s produljenim oslobađanjem, u kutiji.
Only one patient switched to pramipexole prolonged-release tablets experienced a drug-related adverse event leading to withdrawal. 
Samo je jedan bolesnik koji je prešao na pramipeksol tablete s produljenim oslobađanjem imao nuspojavu povezanu s lijekom koja je dovela do prekida terapije.
During the first week, the usual dose is 1 tablet Oprymea 0.088 mg three times a day (equivalent to 0.264 mg daily): 
Tijekom prvog tjedna, uobičajena doza je 1 tableta lijeka Oprymea od 0,088 mg tri puta dnevno (što odgovara 0,264 mg dnevno):
(eating more food than normal and more than is needed to satisfy your hunger)* - Mania (agitation, feeling elated or over-excited)* - Delirium (decreased awareness, confusion, loss of reality)* 
(jedenje veće količine hrane nego što je normalno i više nego je potrebno za utaženje gladi)* manija (agitacija, osjećaj ushita ili pretjeranog uzbuđenja)* delirij (poremećaj svijesti, konfuzija, gubitak osjećaja za stvarnost)*
If you experience these side effects, you must not drive or operate machinery. 
Ako primijetite takve nuspojave, ne smijete upravljati vozilima ili strojevima.
Since the daily dose for the treatment of Restless Legs Syndrome will not exceed 0.54 mg of base (0.75 mg of salt) Oprymea can be discontinued without tapering off. 
S obzirom da dnevna doza u liječenju sindroma nemirnih nogu neće prelaziti 0,54 mg baze (0,75 mg soli), liječenje lijekom Oprymea se može prekinuti bez postupnog snižavanja doze.
The primary endpoint was change from baseline on the Total Tic Score (TTS) of the Yale Global Tic Severity Scale (YGTSS). 
Total Tic Score) u tzv. Yale Global Tic Severity Scale (YGTSS) u odnosu na početne vrijednosti.
There is no relevant use of Oprymea in the paediatric population for the indication of Parkinson's Disease. 
Nema relevantne primjene lijeka Oprymea u pedijatrijskoj populaciji za indikaciju Parkinsonove bolesti.
A lower maintenance dose of three Oprymea 0.088 mg tablets a day is also possible. 
Također je moguća niža doza održavanja od tri Oprymea 0,088 mg tablete dnevno.
- Vision impairment. 
Oštećenje vida.
- The other ingredients are mannitol, maize starch, pregelatinised maize starch, povidone K25, colloidal anhydrous silica and magnesium stearate. 
Drugi sastojci su manitol, kukuruzni škrob, prethodno geliran kukuruzni škrob, povidon K25, koloidni bezvodni silicijev dioksid i magnezijev stearat.
TREATMENT INITIATION PACK ONLY PARTICULARS TO APPEAR ON THE OUTER PACKAGING 
PAKIRANJE SAMO ZA POČETNO LIJEČENJE PODACI KOJI SE MORAJU NALAZITI NA VANJSKOM PAKIRANJU
21 prolonged-release tablets: EU/1/08/469/054 
21 tableta s produljenim oslobađanjem: EU/1/08/469/054
TREATMENT INITIATION PACK ONLY MINIMUM PARTICULARS TO APPEAR ON BLISTERS OR STRIPS 
PAKIRANJE SAMO ZA POČETNO LIJEČENJE PODACI KOJE MORA NAJMANJE SADRŽAVATI BLISTER ILI STRIP
Oprymea is not recommended for use in children and adolescents below 18 years due to a lack of data on safety and efficacy. 
Primjena lijeka Oprymea se ne preporučuje u djece i adolescenata u dobi do 18 godina zbog nedostatnih podataka o sigurnosti i djelotvornosti.
In a Phase I trial, where pramipexole immediate release and prolonged-release tablets were assessed in fasted state, the minimum and peak plasma concentration (Cmin, Cmax) and exposure (AUC) of the same daily dose of pramipexole prolonged-release tablets given once daily and pramipexole tablets given three times a day were equivalent. 
U ispitivanju faze I, u kojem su ocjenjivane pramipeksol tablete s trenutnim oslobađanjem i pramipeksol tablete s produljenim oslobađanjem natašte, minimalne i maksimalne koncentracije u plazmi (Cmin, Cmax) i ekspozicija (AUC) jednakoj dnevnoj dozi pramipeksol tableta s produljenim oslobađanjem, primjenjivanih jedanput dnevno i pramipeksol tableta primjenjivanih tri puta dnevno, bile su jednake.
For patients requiring additional symptomatic relief, the dose may be increased every 4-7 days to a maximum of 0.54 mg of base (0.75 mg of salt) per day (as shown in the table below). 
Za bolesnike kojima je potrebno dodatno ublažavanje simptoma doza se može povećavati svakih 4-7 dana, maksimalno do 0,54 mg baze (0,75 mg soli) dnevno, kao što je prikazano u donjoj tabeli.
During the first week, the usual daily dose is 0.26 mg pramipexole. 
Tijekom prvog tjedna uobičajena dnevna doza je 0,26 mg pramipeksola.
Warnings and precautions Talk to your doctor before taking Oprymea. 
Obratite se svom liječniku prije nego uzmete lijek Oprymea.
Boxes of 20, 30, 60, 90 and 100 tablets in blisters of 10 tablets are available. 
Dostupne su kutije od 20, 30, 60, 90 i 100 tableta u blisterima od 10 tableta.
The most commonly (≥ 5%) reported adverse drug reactions in patients with Parkinson's disease more frequent with pramipexole treatment than with placebo were nausea, dyskinesia, hypotension, dizziness, somnolence, insomnia, constipation, hallucination, headache and fatigue. 
Najčešće (≥5%) prijavljene nuspojave u bolesnika s Parkinsonovom bolešću, češće kod liječenja pramipeksolom nego placebom, bile su mučnina, diskinezija, hipotenzija, omaglica, somnolencija, nesanica, konstipacija, halucinacija, glavobolja i umor.
Because of possible additive effects, caution should be advised when patients are taking other sedating medicinal products or alcohol in combination with pramipexole (see sections 4.4, 4.7 and 4.8). 
Zbog mogućih dodatnih učinaka, oprez je potreban u bolesnika koji uzimaju sedative ili alkohol u kombinaciji s pramipeksolom (vidjeti dijelove 4.4, 4.7 i 4.8).
You can take Oprymea with or without food. 
Možete uzimati lijek Oprymea sa ili bez hrane.
In advanced Parkinson's disease, pramipexole doses higher than 1.1 mg of base (1.5 mg of salt) per day can be useful in patients where a reduction of the levodopa therapy is intended. 
U uznapredovaloj Parkinsonovoj bolesti, dnevne doze više od 1,1 mg baze (1,5 mg soli) mogu biti korisne u bolesnika kojima se namjerava sniziti terapija levodope.
Within the system organ classes, adverse reactions are listed under headings of frequency (number of patients expected to experience the reaction), using the following categories: very common (≥ 1/10); common (≥ 1/100 to < 1/10); uncommon (≥ 1/1,000 to < 1/100); rare (≥ 1/10,000 to < 1/1,000); very rare (< 1/10,000); not known (cannot be estimated from the available data . 
U klasifikaciji prema organskim sustavima, nuspojave su navedene prema učestalosti (broj bolesnika u kojih se očekuje nuspojava), uz uporabu sljedećih kategorija: vrlo često (≥1/10); često (≥1/100 do <1/10); manje često (≥1/1000 do <1/100); rijetko (≥1/10 000 do <1/1000); vrlo rijetko (<1/10 000); nepoznato (ne može se procijeniti iz dostupnih podataka).
In advanced Parkinson's disease, pramipexole doses higher than 1.05 mg of base (1.5 mg of salt) per day can be useful in patients where a reduction of the levodopa therapy is intended. 
U uznapredovaloj Parkinsonovoj bolesti, dnevne doze pramipeksola više od 1,05 mg baze (1,5 mg soli) mogu biti korisne u bolesnika kojima se namjerava sniziti doza levodope.
In patients with a creatinine clearance between 20 and 50 ml/min, the initial daily dose of Oprymea should be administered in two divided doses, starting at 0.088 mg of base (0.125 mg of salt) twice a day (0.176 mg of base/0.25 mg of salt daily). 
U bolesnika s klirensom kreatinina između 20 i 50 ml/min, početna dnevna doza lijeka Oprymea treba se podijeliti u dvije odvojene doze, počevši od 0,088 mg baze (0,125 mg soli) dva puta dnevno (0,176 mg baze/0,25 mg soli dnevno).
Within the system organ classes, adverse reactions are listed under headings of frequency (number of patients expected to experience the reaction), using the following categories: very common (≥ 1/10); common (≥ 1/100 to < 1/10); uncommon (≥ 1/1,000 to < 1/100); rare (≥ 1/10,000 to < 1/1,000); very rare (< 1/10,000); not known (cannot be estimated from the available data). 
U klasifikaciji prema organskim sustavima, nuspojave su navedene prema učestalosti (broj bolesnika u kojih se očekuje nuspojava), uz uporabu sljedećih kategorija: vrlo često (≥ 1/10); često (≥ 1/100, do < 1/10); manje često (≥ 1/1000 do < 1/100); rijetko (≥ 1/10 000 do < 1/1000); vrlo rijetko (< 1/10 000); nepoznato (ne može se procijeniti iz dostupnih podataka).
Dose adjustment in patients with hepatic failure is probably not necessary, as approx. 90% of absorbed active substance is excreted through the kidneys. 
Prilagođavanje doze u bolesnika s oštećenom funkcijom jetre vjerojatno nije potrebno jer se oko 90% apsorbirane djelatne tvari izlučuje putem bubrega.
Blister (week 1) 
Blister (1. tjedan)
Oprymea should not be used during breast-feeding. 
Oprymea se ne smije primjenjivati tijekom dojenja.
Oprymea can have a major influence on the ability to drive and use machines. 
Oprymea može značajno utjecati na sposobnost upravljanja vozilima i rada sa strojevima.
There is no relevant use of Oprymea prolonged-release tablets in the paediatric population for the indication of Parkinson's Disease. 
Nema relevantne primjene Oprymea tableta s produljenim oslobađanjem u pedijatrijskoj populaciji za indikaciju Parkinsonove bolesti.
Based on the analysis of pooled placebo-controlled trials, comprising a total of 1,778 Parkinson's disease patients on pramipexole and 1,297 patients on placebo, adverse drug reactions were frequently reported for both groups. 
Na temelju analize zbirnih podataka iz placebom kontroliranih ispitivanja, koja su obuhvatila 1778 bolesnika s Parkinsonovom bolešću na pramipeksolu i 1297 bolesnika na placebu, nuspojave su se često prijavljivale za obje grupe.
Blister (week 2) 
Blister (2. tjedan)
Uncommon (≥1/1,000 to 
Manje često (≥1/1000 i
Pramipexole was not teratogenic in rats and rabbits but was embryotoxic in the rat at maternally toxic doses. 
Pramipeksol nije bio teratogen u štakora i zečeva, ali je bio embriotoksičan u štakora primijenjen u dozama toksičnim za majku.
The recommended starting dose of Oprymea is 0.088 mg of base (0.125 mg of salt) taken once daily 2-3 hours before bedtime. 
Preporučena početna doza lijeka Oprymea je 0,088 mg baze (0,125 mg soli) jedanput dnevno 2-3 sata prije spavanja.
Hallucinations are known as a side-effect of treatment with dopamine agonists and levodopa. 
Halucinacije su poznata nuspojava liječenja agonistima dopamina i levodopom.
Blister (week 3) 
Blister (3. tjedan)
Oprymea is not recommended for use in children and adolescents below 18 years since the efficacy and safety has not been established in this population. 
Primjena lijeka Oprymea se ne preporučuje u djece i adolescenata u dobi do 18 godina jer njihova sigurnost i djelotvornost nisu ustanovljene za ovu populaciju.
No studies on the effect on human fertility have been conducted. 
Nisu dostupni podaci o plodnosti u ljudi.
Placebocontrolled clinical trials included approximately 1,800 patients of Hoehn and Yahr stages I - V treated with pramipexole. 
Placebom kontrolirana klinička ispitivanja uključila su oko 1800 bolesnika sa stadijem I-V po Hoehn i Yahru liječenih pramipeksolom.
In clinical studies and post-marketing experience cardiac failure has been reported in patients with pramipexole. 
U kliničkim studijama i tijekom razdoblja nakon izdavanja odobrenja za stavljanje lijeka u promet prijavljeno je zatajenje srca u bolesnika na pramipeksolu.
The once daily administration of pramipexole prolonged-release tablets causes less frequent fluctuations in the pramipexole plasma concentration over 24 hours compared to the three times daily administration of pramipexole immediate release tablets. 
Jednokratna dnevna primjena pramipeksol tableta s produljenim oslobađanjem rjeđe izaziva fluktuacije u koncentracijama pramipeksola u plazmi tijekom 24 sata u usporedbi s trokratnom dnevnom primjenom pramipeksol tableta s trenutnim oslobađanjem.
Dose adjustment in patients with hepatic failure is not required, as approx. 90% of absorbed active substance is excreted through the kidneys. 
Podešavanje doze u bolesnika sa zatajenjem jetre nije potrebno, s obzirom da se oko 90% apsorbirane djelatne tvari izlučuje putem bubrega.
The dose will be increased every 5-7 days as directed by your doctor until your symptoms are controlled (maintenance dose). 
Doza se povisuje svakih 5-7 dana prema uputi liječnika, dok se Vaši simptomi ne stave pod kontrolu (doza održavanja).
During dose escalation in pivotal studies, efficacy was observed starting at a daily dose of 1.05 mg of base (1.5 mg of salt). 
Pri povećavanju doze, u pivotalnim studijama, djelotvornost je primijećena počevši od dnevne doze od 1,05 mg baze (1,5 mg soli).
In patients with a creatinine clearance less than 20 ml/min, the daily dose of Oprymea should be administered in a single dose, starting at 0.088 mg of base (0.125 mg of salt) daily. 
U bolesnika s klirensom kreatinina manjim od 20 ml/min, lijek Oprymea je potrebno primijeniti u jednokratnoj dozi, počevši s 0,088 mg baze (0,125 mg soli) dnevno.
The symptoms include: - akinesia (loss of muscle movement) - rigid muscles - fever - unstable blood pressure - tachycardia (increased heart rate) - confusion - depressed level of consciousness (e.g. coma). 
Simptomi uključuju sljedeće: akinezija (gubitak pokretnosti mišića) ukočenost mišića vrućica nestabilni krvni tlak tahikardija (ubrzan rad srca) smetenost smanjena razina svijesti (npr. koma).
Most hallucinations are visual - Dyskinesia (e.g. abnormal, uncontrolled movements of the limbs). 
Diskinezija (npr. abnormalni, nekontrolirani pokreti udova).
Based on the analysis of pooled placebo-controlled trials, comprising a total of 1,923 patients on pramipexole and 1,354 patients on placebo, adverse drug reactions were frequently reported for both groups. 
Na temelju analize zbirnih podataka iz placebom kontroliranih ispitivanja, koja su obuhvatila 1923 bolesnika na pramipeksolu i 1354 bolesnika na placebu, nuspojave su se često prijavljivale za obje skupine.
After that, your doctor may increase the dosing frequency to one 0.26 mg prolonged-release tablet every day. 
Nakon toga, liječnik će povisiti učestalost doziranja na jednu 0,26 mg tabletu s produljenim oslobađanjem svaki dan.
Very rare may affect up to 1 in 10,000 people 
Vrlo rijetko mogu se javiti u do 1 na 10 000 osoba
Symptoms include apathy, anxiety, depression, fatigue, sweating and pain (see section 
Simptomi uključuju apatiju, anksioznost, depresiju, umor, znojenje i bol (vidjeti dio 4.4).
There is no established antidote for overdose of a dopamine agonist. 
Nije poznat specifični antidot za predoziranje s agonistom dopamina.
Table 1: Parkinson's disease Body System Very common 
Tablica 1: Parkinsonova bolest
Oprymea is indicated in adults for treatment of the signs and symptoms of idiopathic Parkinson's disease, alone (without levodopa) or in combination with levodopa, i.e. over the course of the disease, through to late stages when the effect of levodopa wears off or becomes inconsistent and fluctuations of the therapeutic effect occur (end of dose or “on off” fluctuations). 
Oprymea je indicirana za liječenje znakova i simptoma idiopatske Parkinsonove bolesti u odraslih, u obliku monoterapije (bez levodope) ili u kombinaciji s levodopom, tj. tijekom trajanja bolesti, pa sve do uznapredovale faze, kada učinak levodope jenjava ili postane nestalan te dolazi do fluktuacija u terapijskom učinku (učinak "kraja doze” ili “on-off” fluktuacije).
In clinical trials approximately 5% of patients were treated at doses below 1.05 mg of base (1.5 mg of salt). 
U kliničkim ispitivanjima je oko 5% bolesnika liječeno dozama nižim od 1,05 mg baze (1,5 mg soli).
A maximum daily dose of 1.1 mg pramipexole base (1.5 mg of salt) should not be exceeded. 
Ne smije se prekoračiti maksimalna dnevna doza od 1,1 mg baze pramipeksola (1,5 mg soli).
In clinical trials approximately 5% of patients were treated at doses below 1.1 mg of base (1.5 mg of salt). 
U kliničkim ispitivanjima je oko 5% bolesnika liječeno dozama nižim od 1,1 mg baze (1,5 mg soli).
Patients must be informed of this and advised to exercise caution while driving or operating machines during treatment with Oprymea. 
Tijekom liječenja lijekom Oprymea bolesnici moraju biti informirani o tome, te ih se mora upozoriti na povećan oprez pri upravljanju motornim vozilima ili strojevima.
If you have to stop taking this medicine, your doctor will reduce the dose gradually. 
Ako morate prekinuti uzimanje lijeka, liječnik će Vam postupno snižavati dozu, čime se smanjuje rizik od pogoršanja simptoma.
10 prolonged-release tablets 30 prolonged-release tablets 90 prolonged-release tablets 100 prolonged-release tablets 
10 tableta s produljenim oslobađanjem 30 tableta s produljenim oslobađanjem 90 tableta s produljenim oslobađanjem 100 tableta s produljenim oslobađanjem
The use of pramipexole has not been studied in haemodialysis patients, or in patients with severe renal impairment. 
Primjena pramipeksola nije ispitivana u bolesnika na hemodijalizi ili bolesnika s teškim bubrežnim oštećenjem.
Common: - Changes in sleep pattern, such as sleeplessness (insomnia) and sleepiness - Tiredness (fatigue) - Headache - Abnormal dreams - Constipation - Dizziness - Vomiting (being sick) 
Često: promjene u obrascu spavanja, kao što su nesanica (insomnija) i pospanost umor (zamor) glavobolja neobični snovi zatvor omaglica povraćanje
In these cases Oprymea may affect your ability to drive and operate machinery. 
U spomenutim slučajevima, Oprymea može utjecati na sposobnost upravljanja vozilima i rada sa strojevima.
3-week treatment initiation pack contains 21 prolonged-release tablets in 3 packages: - the package marked "Week 1" contains 1 blister of 7 tablets of 0.26 mg, - the package marked "Week 2" contains 1 blister of 7 tablets of 0.52 mg, - the package marked "Week 3" contains 1 blister of 7 tablets of 1.05 mg. 
Pakiranje za 3-tjedno početno liječenje sadrži 21 tabletu s produljenim oslobađanjem u 3 pakiranja: pakiranje s oznakom „1. tjedan" sadrži 1 blister sa 7 tableta od 0,26 mg.
Do not try to make up for the missed dose. 
Nemojte uzeti dvostruku dozu kako biste nadoknadili zaboravljenu dozu.
How to take Oprymea 
Kako uzimati lijek Oprymea
If you accidentally take too many tablets, - Contact your doctor or nearest hospital casualty department immediately for advice. 
Trenutno se javite liječniku ili na odjel najbliže bolnice za savjet.
Cardiac disorders cardiac failure 
Srčani poremećaji zatajenje srca
If you are switching from Oprymea (immediate release) tablets Your doctor will base your dose of Oprymea prolonged-release tablets on the dose of Oprymea (immediate release) tablets you were taking. 
Liječnik će započeti s dozom Oprymea tableta s produljenim oslobađanjem adekvatno Vašoj dozi Oprymea tableta (s trenutnim oslobađanjem) koju ste uzimali.
Parkinson's disease The daily dose is to be taken divided into 3 equal doses. 
Dnevna doza se uzima podijeljena u 3 jednake doze.
Very common: - Dyskinesia (e.g. abnormal, uncontrolled movements of the limbs) - Sleepiness - Dizziness - Nausea (sickness) 
Vrlo često: diskinezija (npr. abnormalni, nekontrolirani pokreti udova) pospanost omaglica mučnina
- The other ingredients are hypromellose, maize starch, colloidal anhydrous silica and magnesium stearate. 
Drugi sastojci su hipromeloza, kukuruzni škrob, bezvodni koloidni silicijev dioksid i magnezijev stearat.